Psoriasis | Pharmacor | G7 | 2014

launch Related Market Assessment Reports

• Psoriasis – Current Treatment – Detailed, Expanded Analysis Adult Psoriasis – Treatment Algorithms – Claims Data Analysis (US)

  April 2023

  Adult psoriasis treatment represents an increasingly lucrative market for biologics in the moderate to severe population, in which conventional systemic and topical treatments alone are not…

• Psoriasis | Disease Landscape & Forecast | G7 | 2022

  December 2022

  The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…

• Psoriasis – Landscape & Forecast – Disease Landscape & Forecast

  December 2022

  The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…

• Psoriasis – Geographic Focus: China – Psoriasis – China In-Depth (China)

  September 2022

  China’s psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2021-2031…

• Psoriasis – Access & Reimbursement – Detailed, Expanded Analysis (US)

  July 2022

  Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor Cosentyx lead the U.S. psoriasis biologics…